Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7119694 | 0.84 | MEN1 (0.53) | KMT2AMEN1RAB9ASMN1; SMN2GAA | |
| SCHEMBL7966390 | 0.81 | CYP1A2 (0.42) | HIF1ATDP1MMP9 | |
| SCHEMBL7114559 | 0.80 | TDP1 (0.49) | KMT2AMEN1RAB9ASMN1; SMN2GAA | |
| SCHEMBL7117219 | 0.74 | CYP3A4 (0.58) | KMT2AMEN1SMN1; SMN2GAAHTT | |
| SCHEMBL6281664 | 0.73 | CYP3A4 (0.59) | KMT2AMEN1POLBLMNAALDH1A1 | |
| SCHEMBL7119899 | 0.72 | RXFP1 (0.46) | KMT2AMEN1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL21264291 | 0.71 | LMNA (0.65) | KMT2AMEN1RAB9ASMN1; SMN2GAA | |
| SCHEMBL7116236 | 0.69 | MAPT (0.51) | KMT2AMEN1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL7800335 | 0.69 | MEN1 (0.47) | KMT2AMEN1RAB9ASMN1; SMN2GAA | |
| SCHEMBL11674236 | 0.69 | LMNA (0.61) | KMT2AMEN1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010036961-A1 | Substituted alkylene diamine compounds | CV THERAPEUTICS, INC. | 2001-11-01 | — | — | US | claimed |
| US-20010036961-A1 | Substituted alkylene diamine compounds | CV THERAPEUTICS, INC. | 2001-11-01 | — | — | US | disclosed |
| WO-2001062711-A2 | SUBSTITUTED ALKYLENE DIAMINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036961-A1 | Substituted alkylene diamine compounds | TNNC1, CPT1B, TNNI3 | KMT2A 3714/4885MEN1 3239/4885POLB 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.